81 results about "Asymptomatic" patented technology

A statistical (a) Computer Aided Diagnostic (CAD) technique is described for symptomatic versus asymptomatic plaque automated classification of carotid ultrasound images and (b) presents a cardiovascular risk score computation. We demonstrate this for longitudinal Ultrasound, CT, MR modalities and extendable to 3D carotid Ultrasound. The on-line system consists of Atherosclerotic Wall Region estimation using AtheroEdge™ for longitudinal Ultrasound or Athero-CTView™ for CT or Athero-MRView from MR. This greyscale Wall Region is then fed to a feature extraction processor which uses the combination: (a) Higher Order Spectra; (b) Discrete Wavelet Transform (DWT); (c) Texture and (d) Wall Variability. Another combination uses: (a) Local Binary Pattern; (b) Law's Mask Energy and (c) Wall Variability. Another combination uses: (a) Trace Transform; (b) Fuzzy Grayscale Level Co-occurrence Matrix and (c) Wall Variability. The output of the Feature Processor is fed to the Classifier which is trained off-line.

The invention discloses a non-invasive detection method and a kit for early screening a bladder cancer by multi-gene combination. The combined genes include APC, NID2 and p16, and specific methylationprimers are designed to detect three nucleotide sequences of target gene fragment methylation of the APC, the NID2 and the p16, so that early screening and auxiliary diagnosis of the bladder cancer are achieved. Methylation levels of three genetic markers of the APC, the NID2 and the p16 in urinary sediments are analyzed by a three-channel fluorescent quantitative PCR (polymerase chain reaction)method, and a positive or negative result of a sample is judged according to a reported CT (computed tomography) value. The non-invasive detection method can detect 90% of early bladder cancers, 64% of precancerous adenomas (larger than or equal to 1 centimeter) in preclinical study, specificity reaches 100%, invasiveness is completely omitted, the method only needs to collect urine of 50mL, and acceptability of throngs wearing no symptoms is high.

The invention discloses a genetic genetic diagnosis kit for amyotrophic lateral sclerosis. The kit and a detection method are characterized in that gene-specific primers are designed and synthesized according to a virulence gene which is studied and reported to be correlated with the amyotrophic lateral sclerosis, including SOD1, FUS, VAPB, ANG, TARDBP, FIG4, OPTN, VCP, Sigmar1, CHMP2B and PFN1 sites, a sample is obtained from an individual to be detected, a RT-PCR technology is carried out, the RT-PCR product is subjected to sequencing analysis, next, the sample sequence is compared with a normal gene sequence to determine whether the sample sequence has disease-causing mutations. The kit is capable of detecting all disease-causing mutation sites of the coding sequence (CDS) of the virulence gene at a time, and has the advantages of being simple and quick, reliable in preparation, good in specificity, high in sensitivity and the like; the kit is capable of detecting the ALS patients and asymptomatic patients.

A SARS virus antigen-antibody vaccine and its experimented method are disclosed. Said composite vaccine is prepared from the SARS virus antigen and specific antibody, and features that it can directly submit said virus antigen to the antigen presenting APC cells and mononuclear/macrophage for exciting the immune response mechanism of lymphatic immune system. Its advantages are high immune effect and specific target treatment to SARS.

The invention discloses a global new coronavirus propagation prediction method based on an optimized SEIRD model, and relates to the technical field of infectious disease data processing, and the method comprises the steps: A, collecting data, and building an improved SEIRD cabin model on the basis of an epidemiological SEIR model: 1, increasing the index of latent crowd infection rate, subdividing the susceptible population conversion rate in the SEIR model into a latent population infection rate and a definite population infection rate; 2, subdividing the removal rate in the SEIR model intoa death rate and a cure rate; 3, expressing the cure rate and the death rate as a time sequence function of time t; dividing crowds in the bin into five types, namely susceptible people, symptomatic latent infected people, symptomatic infected people, cured people and dead people; B, respectively carrying out parameter estimation and model fitting on the model according to a least square method, estimating an inflection point and an end date of an epidemic situation, and carrying out model inspection by using actual data. The method has the advantages of accurate prediction and good reliability.

The invention relates to the field of biological information technology and medical health, and discloses a network trio motif consisting of vaginal bacteria and application of the network triangular motif aiming at personalized risk assessment, precise diagnosis, treatment and post-healing (return visit monitoring) of female Bacteria Vaginosis (BV). Based on a dominance network analysis framework, the inventor analyzes and compares vaginal microbial florae of healthy individuals and BV patients, 15 bacterial network trio motifs specific to the BV patients are screened from the vaginal microbial florae, twelve trio motifs are specific to symptomatic BV patients, and the other three trio motifs appear in both symptomatic and asymptomatic BV patients. Each network motif is formed by connecting three vaginal bacteria species through a specific interaction relationship. The network trio motif composed of the vaginal bacteria can be used for diagnosis and risk assessment of the BV, and provides a brand new target for personalized precise treatment and post-healing monitoring of the BV.

The embodiment of the invention provides a method and device for predicting an infectious disease trend based on an asymptomatic infected person. The method comprises the following steps: acquiring known epidemic situation data of a target infectious disease in a preset time period; according to the known epidemic situation data, determining the current removal probability of the asymptomatic infected person in the incubation period and the infection ability indexes of the asymptomatic infected person in different periods; and predicting epidemic situation data of the target infectious diseasein the future according to the probability that the asymptomatic infected person is currently removed in the incubation period, the infection ability indexes of the different periods, the known epidemic situation data and a pre-trained infectious disease model for the target infectious disease. In the susceptibility stage, the incubation stage and the removal stage, the influence of the asymptomatic infectors is fused, and the infection sequence of the asymptomatic infectors is increased in the sensory disease model, so that the prediction accuracy of the infectious disease model is improved.

The invention belongs to the field of epidemic emergency decision-making, and provides a joint decision-making system and method for data-driven epidemic detection and medical resource allocation. The system and method can continuously learn and improve the prediction and estimation of the number of susceptible persons, asymptomatic infected persons, symptomatic infected persons and convalescent persons and the propagation parameters of an epidemic based on continuously updated confirmed case data and epidemic detection result data; and aiming at minimizing the total number of future infected persons, the system and method dynamically carry out joint decision making on epidemic monitoring and medical resource allocation. With the system and method of the invention adopted, epidemic development can be predicted on the basis of the limited diagnosed case data and epidemic detection data, decision-making based on prediction is achieved, the total number of infected people is reduced, and the perspectiveness, effectiveness and scientificity of decision-making are improved.

An application for tracking infectious disease including an input module for inputting variables from a user in electronic communication with an output variable module, an analysis module for analyzing input variables and output variables, and an output module for presenting results to the user. A method of tracking infectious disease, by a user inputting data about symptoms of infectious disease and user defined metrics in an application, performing an analysis on the data, and outputting a result from the data tracking symptom progression, tracking geolocation of symptoms and outbreaks, and tracking trends among individuals without symptoms and individuals with different diseases. A method of monitoring the health of employees and students.

The invention discloses a detection kit for detecting a novel coronavirus. The kit comprises an anti-2019-nCoV IgM reaction conjugate, an anti-2019-nCoV IgG reaction conjugate, a 2019-nCoV IGRAs reaction conjugate, an anti-2019-nCoV IgM marker, an anti-2019-nCoV IgG marker, a 2019-nCoV IGRAs marker and the like. The kit disclosed by the invention has the advantages that the detection results of the anti-2019-nCoV IgM, the anti-2019-nCoV IgG and the 2019-nCoV IGRAs are combined; the kit is helpful for early auxiliary diagnosis of the 2019-nCoV in the acute infection period and the recurrence period, judgment of recent infection and long-term infection of the 2019-nCoV, and auxiliary diagnosis of dominant infectors and recessive infectors when antibodies of the 2019-nCoV infectors do not appear. Positive infected people can be detected and confirmed more simply, conveniently, rapidly and accurately, the detection rate of novel coronavirus nucleic acid negative suspected patients is increased, and light or asymptomatic novel coronavirus pneumonia restorers are tracked.

The invention discloses a method and a kit for predicting the risk of neurodegenerative diseases. According to the method, based on the level of biomarkers in a biological sample, the risk of neurodegenerative diseases in subjects is predicted, wherein the biomarkers are growth-related protein 43 (GAP43), neurogranin, synaptosome-associated protein 25 (SNAP25), and synaptotagmin 1. The method disclosed by the invention can be used for detecting the AD in an asymptomatic period, even can be used for predicting the AD suffering risk of a subject 5-7 years before onset of the AD, and has the advantages of almost no wound, low risk and the like.

The invention belongs to the field of biological medicines, and relates to an application of baicalin in preparation of a medicine for preventing and/or treating asymptomatic hyperuricemia and/or uricacid nephropathy. Based on animal and cell experiments, the effect of baicalin on hyperuricemia nephropathy is studied, and the result shows that baicalin can inhibit the activity of xanthine oxidase, inhibit uric acid generation, reduce the serum uric acid level of mice with uric acid nephropathy and remarkably improve the renal function of the mice. The baicalin inhibits damage of sodium uratecrystals to rat renal tubular epithelial cells by reducing secretion of TNF alpha, IL-1beta, lactate dehydrogenase and NO.

The invention discloses a marker and a probe composition for gastric cancer screening and application of the marker and the probe composition. The marker is selected from any one of 47 markers. According to the present invention, with the application of the marker, the methylation state of the gene can be sensitively and specifically detected so as to be used for the detection of the peripheral blood free DNA, and the composition is used for the screening of the asymptomatic population in the non-invasive manner so as to reduce the harm caused by the invasive detection; the composition has higher sensitivity and accuracy, and can realize real-time monitoring.

The invention belongs to the field of biotechnology application, and relates to a novel prediction technology for human severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) infection, inparticular to a method for determining the content of an active urokinase receptor in a human body through enzyme-linked immunosorbent assay to serve as a prognosis biomarker of a COVID-19 patient. Bydetecting the level of an active urokinase receptor in a COVID-19 patient, an asymptomatic infector or a healthy human body, it is found that the level of active suPAR in the COVID-19 patient and theasymptomatic infector is far higher than that of active suPAR in the healthy human body, and the level of active suPAR in the asymptomatic infector is slightly higher than that of active suPAR in theCOVID-19 patient. The result obtained by the invention shows that the detection of the level of the suPAR in the body of the COVID-19 patient can be used as a prognosis biomarker of the patient, anda certain value is provided for early triage of the COVID-19 patient.

The present invention belongs to the technical field of bioengineering and biomedicine, and specifically relates to the field of oncology and more specifically to a set of early esophageal squamous cell carcinoma screening markers and an application of the markers in a primer probe kit. The present invention provides a primer composition and a probe composition for detecting SLAMF1, CRIM, CCSER1,MGARP, and POMK genes. Besides, the primer composition and probe composition are utilized to prepare the kit for detecting early esophageal squamous cell carcinoma. The detection sensitivity of the kit for the early esophageal squamous cell carcinoma reaches 82.11% and the specificity reaches 86.99%. The kit is suitable for large-scale screening of the early esophageal squamous cell carcinoma of asymptomatic people in a high-incidence area of the esophageal squamous cell carcinoma.

The invention discloses a probe composition. According to the composition, through meta analysis of methylation data of a TCGA database and a GEO database, a 4.29 Kbp capture region is screened out, the 4.29 Kbp capture region comprises up to 37 methylation change genes highly related to cancer and non-coding DNA regions, and the method can detect methylation level changes of three kinds of lumen organ cancers such as esophageal cancer, gastric cancer and colorectal cancer at a time. The probe composition can be used for early screening of asymptomatic people and prognosis detection of cancer patients, and the breadth of detection genes of the probe compositino is superior to that of detection genes in the prior art and products.

The invention belongs to the field of molecular biology and oncology, and particularly discloses the application of a combination of FAM84A protein, USP15 protein, FAM212B protein, ALDH3A1 protein andRAB33B protein in an esophageal cancer detection colloidal gold test strip or a kit. The present invention also discloses the colloidal gold test strip for screening and early discovering the asymptomatic high-risk groups. The colloidal gold test strip comprises a bottom plate, and a sample pad, a colloidal gold labeled combination pad, a nitrocellulose membrane and a water absorption pad which are sequentially connected from one end of the bottom plate are arranged on the bottom plate. The colloidal gold test strip provided by the invention improves the sensitivity and specificity of esophageal cancer symptomless high-risk group screening and early esophageal cancer, and when the five tumor markers are combined at the same time, the detection effect reaches the best (the sensitivity is 92.3%, and the specificity is 98.3%).

This disclosure relates to a screening test method, device, and kit for carbohydrates found in a biological sample and associated conditions including, cancerous and precancerous conditions. Specifically, the method tests abnormal carbohydrates in a biological sample using reagents of galactose oxidase, and Schiff's Reagent. The screening test method, device, and kit provides expanded testing capabilities across a range of known conditions and in an otherwise healthy population. This disclosure further relates to the use of the device or kit for an initial evaluation for cancerous and precancerous conditions in people without obvious signs and symptoms, and cancer recurrence in at point-of-care facility or at home.

The present invention relates to a rapid, high-throughput detection method for screening of potential casualties exposed to a cholinesterase inhibitor. A kit is provided for conducting the method that requires only a small volume of sample such as blood for detection and has a rapid screening throughput for multiple casualties. The kit is able to detect both free and protein-bound-cholinesterase inhibitors. The method should be able to differentiate asymptomatic exposure from the mass psychogenic illness cases.

The present invention belongs to the field of traditional Chinese medicines and particularly relates to a qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula and a preparation method and an application thereof. The qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula comprises the following food materials in parts by weight: 6-15 parts of sun-dried ginseng or American ginseng, 1-6 parts of dried orange peel, 1-3 parts of Chinese olives, 3-15 parts of fresh ginger and 250-500 parts of lean meat. The present invention also providesthe preparation method and the application of the qi-tonifying, dampness-eliminating and sore-throat-relieving dietary therapy formula. The dietary therapy formula is suitable for asymptomatic patients with novel coronavirus infection, people with mild symptoms of weakness of the spleen and the stomach, short breath and hypodynamia after activities, qi deficiency and lassitude, thirst and dry throat, dry tongue and little body fluid, dry stool or little qi and vain straining, and people with mild symptoms of weakness, chronic pharyngitis, cough, throat itching, dry throat, pharyngalgia, hoarseness and hypodynamia. Meanwhile, the dietary therapy formula also has effects of relieving symptoms such as fever, cough, dry throat, throat itching, sore throat, hoarseness, hypodynamia and the likecaused by influenza and acute upper respiratory tract infection (such as common cold, viral pharyngitis, laryngitis, herpangina and the like).

The invention belongs to the technical field of medical biology, and particularly discloses a marker and a kit for diagnosing esophageal squamous carcinoma. The marker for diagnosing the esophageal squamous carcinoma, provided by the invention, is at least one of S-sulfo-L cysteine, symmetric dimethylarginine and 4-methoxyphenylacetic acid, and a detection reagent of the marker can be used for preparing a product for diagnosing the esophageal squamous carcinoma. The invention also provides a kit for diagnosing esophageal squamous carcinoma, the kit contains a detection reagent for detecting the marker, and the detection reagent is a reagent for detecting the marker in a sample through chromatography-mass spectrometry or chromatography-mass spectrometry. By detecting the expression levels of S-sulfo-L cysteine, symmetric dimethylarginine and 4-methoxyphenylacetic acid in human serum, esophageal squamous cell carcinoma can be effectively detected, the detection sensitivity reaches up to 80%, the specificity reaches up to 71%, and the kit can be used for large-scale screening of asymptomatic crowds in high-incidence areas of esophageal squamous cell carcinoma, and screening and early detection of asymptomatic high-risk groups are facilitated.

The invention provides a kit and a device for screening a new coronal pneumovirus asymptomatic infected person. According to the kit and the device for screening the new coronal pneumovirus asymptomatic infected person, in the screening process, the accuracy is good, the Youden index is 0.82, and the clinical requirements on a screening method can be met. Compared with a throat swab nucleic acid detection reagent and a serological antigen-antibody reagent in the prior art, the throat swab nucleic acid detection reagent can effectively overcome the defect that the risk of virus propagation is increased due to missed diagnosis caused by the reason that an asymptomatic infection patient has no obvious symptoms, viruses are not easy to fall off, false negative is easy to appear in nucleic acid detection and the like; secondly, by collecting the urine sample in a non-invasive mode and detecting and screening hypoxanthine, uric acid and dihydro-5-pentyl-2 (3H)-furanone in the urine sample, the method is convenient and rapid, low in infection risk and harmless to patients, and has clinical application and popularization value.